A recent study confirmed the excellent in vitro activity of ME1036 against multidrug-resistant clones of S. pneumoniae involved in severe invasive disease and indicated a potential role for ME1036 in the treatment of hospitalized patients with severe respiratory tract infections. 5 In this current study, we evaluated the activity of ME1036 and comparators against clinical blood culture isolates from patients with bacteraemic communityacquired pneumonia (CAP) requiring hospitalization. These same isolates had previously been used to investigate the activity of ceftaroline. 6 The following isolates from various worldwide locations between 2000 and 2006 were investigated: 1007 S. pneumoniae, 119 H. influenzae, 164 S. aureus, 38 S. pyogenes and 9 Moraxella catarrhalis. MICs were determined using CLSI broth microdilution methodology.
7,8 Susceptibility categories were determined for most antimicrobials using CLSI breakpoints.
8,9 Tigecycline susceptibilities were categorized using US Food and Drug Administration (FDA)-approved breakpoints, 10 which, amongst the isolates included in this study, are available for susceptible or non-susceptible S. aureus only.
Summary MIC data for ME1036 are shown in Table 1 These data show that ME1036 is an enhanced-spectrum b-lactam with excellent activity against CAP isolates causing serious invasive infections, including MRSA and other b-lactam-resistant strains. The results of the present study confirm and extend previous findings for ME1036 as reported by others. 1 -4 ME1036 exhibits a spectrum of in vitro activity that suggests it has the potential to be a useful addition to the treatment options for serious hospitalized CAP patients. 
